Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, dedicated to developing innovative therapies for hypertension and related cardiovascular conditions. The company boasts a strong pipeline of drug candidates designed to address significant unmet medical needs in the cardiovascular sector. With a strategic focus on advancing patient care and improving treatment outcomes, Mineralys is well-positioned to become a key player in redefining the therapeutic landscape for individuals affected by chronic cardiovascular diseases.